JG FNP-BC (@soonergise) header
JG FNP-BC (@soonergise) profile picture

Family Nurse Practitioner

Dallas, TX, USA
Joined April 2011
Photo by JG FNP-BC (@soonergise)Photo by JG FNP-BC (@soonergise)Photo by JG FNP-BC (@soonergise)Photo by JG FNP-BC (@soonergise)Photo by JG FNP-BC (@soonergise)Photo by JG FNP-BC (@soonergise)
JG FNP-BC retweeted
Palmer Luckey on why he believes Elon Musk shouldn't have to risk the entire Starlink network for Ukraine when the U.S. government isn't willing to take the same risk with Starshield.
257
788
112
7,081
563,424
Additional thoughts on HORIZON: The trial ran longer than planned because the observed MACE rate was lower than the design assumption of 4.6%/yr (MACE-4), most likely based on FOURIER-like populations. Actual placebo rate was ~2.6–2.7%/yr. The neutral result (HR ~1.0) shows this was not a pelacarsen treatment effect. Lp(a)HORIZON was younger (~60 yr) and more intensively treated (78% high-intensity statin, 57% ezetimibe/BAS, 11% PCSK9i, SBP 125, LDL-C ~65, hsCRP 0.8). Rough adjustment for age, LDL-C, and diabetes closes roughly half the gap to FOURIER on 3-point MACE. The rest is plausibly background therapy, smoking, and inflammation—though these are overlapping, unadjusted estimates. Bottom line: the low rate is mostly a population effect (younger patients with premature disease + excellent risk-factor control), not evidence of a general fall in secondary-prevention event rates. This also emphasizes the importance of primary prevention in patients with elevated Lp(a)
7
5
39
2,540
The Lp(a)HORIZON has created a huge controversy on the field. To the point of calling Lp(a) as "DEAD". Let's briefly overview why is this not true and how to interpret adequately the trial (🧵) My take on the evidence so far. And what was the word on the #AHA2026 hallways.
5
10
34
3,176
Prior to HORIZON we told our patients with elevated Lp(a) that lowering LDL-c to < 55mg/dl and and improving hs-CRP to < 2mg/L ( predominantly by weight loss) that CV risk will be potentially mitigated. HORIZON demonstrates that our recommendations were correct. Attached are figures in the NEJM Supplement that show this very clearly. In the Placebo arm with LDL-C < or > 70 the MACE rate is 10.2 vs 14.8% (45% higher) and CRP < or > 2 is 10.8 vs 16.6% (64% higher). In the subgroups with Lp(a) above or below the median the MACE were basically equivalent. Therefore in the setting of a modestly elevated LDL or CRP the CV risk is markedly elevated in high Lp(a) patients compared to those with low LDL/CRP. Therefore HORIZON teaches us that although lowering Lp(a) with an ASO does not modify the risk we can continue to confidently inform Lp(a) elevated patients of the need to aggressively lower LDL and inflammation (CRP). Much appreciation to Steve Nissen et al and Novartis for a landmark CVOT.
12
40
7
161
37,522
JG FNP-BC retweeted
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels. 1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients. 2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly. 3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering. 4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se. 5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent. 6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason. 7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future. 8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a). I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field. And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies, I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future. With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future. Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
52
121
18
546
62,833
He’s still here. He’s got a fan club. Including us.
19,802
24,299
5,419
231,007
8,483,515
No. You aren't immune to elevated ApoB... nitter.cf/nicknorwitz/status/211…
Are You “Immune” to High ApoB? 🧵🔥 1/4) Does high ApoB only matter when you have poor metabolic health? A new study published in the European Journal of Preventative Cardiology reads, “When HDL-C is high, the effect of changing ApoB vanishes.” Not diminish. “Vanishes.”  Now, look at this…
3
3
1,079
Them: ApoB didn't correlate with plaque progression. Us: Wait...that wasn't your preregistered primary outcome. Them: Plaque begets plaque Us: Wait...your study shows LMHRs have historically high plaque progression. Them: The data is wrong because our vendor sucks. Us: Why did you go on a historic marketing campaign and produce a documentary? Them: We retracted our paper. All good. Us : That's not how this works.
12
17
5
162
21,964
JG FNP-BC retweeted
#MedNews: Reducing lipoprotein(a) levels was widely assumed to be the next big breakthrough in cardiovascular disease, and European and US clinical guidelines already recommend measuring Lp(a) in all adults. But after the Lp(a)-lowering agent pelacarsen failed to prevent major adverse cardiovascular events in a phase 3 trial, many are wondering what comes next. ja.ma/4eDQQoX
9
44
1
159
20,764
A ‘RED RISING’ movie is in the works at Paramount • Francis Lawrence (‘The Hunger Games: Catching Fire’) set to direct • The story follows a young miner living on Mars who attempts to bring down the color-coded class system (Source: hollywoodreporter.com/movies…)
763
3,423
3,118
38,668
3,776,312
JG FNP-BC retweeted
An AI-based healthcare startup will start offering dermatology prescriptions to Utah patients without a doctor's oversight. bloomberg.com/news/articles/…
12
29
29
104
150,343
👉Atorvastatin & Lp(a): Does Statin Choice Matter? ☝️Lp(a) oxidation appears to accelerate nonlinearly as Lp(a) enrichment increases 1️⃣ Lp(a)-enriched particles oxidize faster than sdLDL and LDL 2️⃣ Hydroxylated atorvastatin metabolites markedly attenuated oxidation—an effect not reproduced by the other statins tested 3️⃣ Could atorvastatin modify the “quality” of Lp(a) even without lowering its concentration? 4️⃣ Could this translate into less Lp(a)-mediated atherogenicity despite unchanged—or even slightly increased—Lp(a) levels? 🤔 Are all statins really equivalent in patients with high Lp(a)? ☝️Mechanistic, in vitro, hypothesis-generating. But a fascinating question for clinical testing. 🔗🔓 jacc.org/doi/10.1016/j.jacbt… @society_eas
9
31
140
8,836
JG FNP-BC retweeted
Hi all, The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint. In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint. We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details. But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.” What we know: 1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong. 2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention. 3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively. 4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial. Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower. 5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients. 6-This raises a very basic question: Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low? What we don’t know: 1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested. 2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles? 3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention. 3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered. 3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data. 4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)? 5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring? 6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting. 7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important. What does this mean for patients today? If you have already had an MI, stroke or PAD, the immediate lesson is very clear: 1- Get all of your established risk factors treated aggressively. 2- Get LDL-C/apoB very low. 3- Control blood pressure. 4- Control diabetes. 5- Don’t smoke. 6- Use appropriate antiplatelet and other guideline-directed therapies. HORIZON shows us what modern secondary prevention should look like. If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk. Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively. We should wait for those trials before drawing broad conclusions about the entire field. I think the story of Lp(a) therapy is beginning, not ending. We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk. More to come as we go forward.
95
311
43
1,093
183,311
HILARIOUS 😂 Woman MOCKS Lindsay Clancy supporters with extreme accuracy‼️ This is the funniest most spot on 🎯 video you will see all day. Mockery is the most effective way to battle back against the insanity.
596
6,481
360
39,790
1,189,130
JG FNP-BC retweeted
Important announcement: I am upping my offer, $10 million dollars for a head-to-head basketball game between the defending WNBA champion Las Vegas Aces and a boy's high school state title team of my choice. If the Aces beat my team, I will give them $10 million.
3,101
10,215
1,173
113,956
10,401,359
JG FNP-BC retweeted
Liberal white women would rather pretend men pretending to be women are women than ensure women’s sports are only played by women. And this is also making a direct political statement during a @wnba game, which means the league endorses this position.
Unreal, man. Minnesota Lynx head coach Cheryl Reeve is wearing a shirt that says "Trans Kids Belong" on the sideline of her team's game against Sophie Cunningham and the Indiana Fever today.
608
2,004
73
12,824
771,478
JG FNP-BC retweeted
The great tragedy of science - the slaying of a beautiful hypothesis by an ugly fact. - Thomas Huxley novonordisk.com/content/nnco…
7
34
4
104
11,231